MutationAssessor and PROVEAN: An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers reverses the order
- Low severity
- Not yet reviewed
- Ordering reversal
- unknown
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks PROVEAN above MutationAssessor in 6 of 6 comparisons; 2 of 2 other studies rank MutationAssessor above PROVEAN.
An automatic lead, not a finding of error. The results below are shown as published, everywhere on the site, until a reviewer decides otherwise.
Which studies agree
5 papers rank MutationAssessor above PROVEAN in 21 of their 38 comparisons and PROVEAN higher in 15; 2 are ties. Of those papers, ProteinGym ranks PROVEAN higher on its own (1 of 1). An openly licensed benchmark… ranks PROVEAN above MutationAssessor in all 6 of its comparisons.
- Rank MutationAssessor higher (3): Livesey and Marsh 2025, Clinical likelihood ratios and balanced…, Brandes et al. 2023
- Rank PROVEAN higher (2): An openly licensed benchmark… (disagrees), ProteinGym
- Mixed (1): Comprehensive assessment…
Each paper sits where at least two thirds of its comparisons point; Mixed means neither model reaches two thirds. The larger, outlined dot is the paper that disagrees.
| Paper | Role | Ranks MutationAssessor higher | Ranks PROVEAN higher | Ties |
|---|---|---|---|---|
| An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers and 1 more record · DOI | Disagrees | 0 | 6 | 0 |
| Comprehensive assessment of computational algorithms in predicting cancer driver mutations and 4 more records · DOI | Agrees | 8 | 12 | 0 |
| Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and 1 more record · DOI | Agrees | 7 | 0 | 0 |
| Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes and 1 more record · DOI | Agrees | 4 | 2 | 0 |
| Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods · DOI | Agrees | 2 | 0 | 2 |
| ProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design and 6 more records · DOI | Agrees | 0 | 1 | 0 |
Comparisons in An openly licensed benchmark… (6)
Comparisons in Comprehensive assessment… (20)
Comparisons in Livesey and Marsh 2025 (7)
| Protocol | Dataset | Metric | MutationAssessor | PROVEAN | Higher |
|---|---|---|---|---|---|
| Livesey and Marsh 2025 clinical benchmark: pairwise AUROC win rate, ClinVar pathogenic versus gnomAD missense | Livesey and Marsh 2025 clinical set: ClinVar pathogenic versus gnomAD v4.1 missense (819 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, per-protein AUROC on shared variants, ClinVar P/LP versus gnomAD v4.1 missense, proteins with at least 10 of each), percent | 51.4 | 48.6 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets), percent | 58.8 | 48.1 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS sets | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets), percent | 10.3 | 5.47 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only), percent | 59.3 | 51 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only), percent | 58.3 | 46 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions only | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only), percent | 58.8 | 48.3 | MutationAssessor |
| Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filled | Livesey and Marsh 2025 human DMS benchmark set (36 proteins) | Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score), percent | 57.3 | 50 | MutationAssessor |
Comparisons in Clinical likelihood ratios and balanced… (6)
Comparisons in Brandes et al. 2023 (4)
Comparisons in ProteinGym (1)
| Protocol | Dataset | Metric | MutationAssessor | PROVEAN | Higher |
|---|---|---|---|---|---|
| ProteinGym clinical substitutions, zero-shot, average AUC (commit 144fe22) | ProteinGym clinical substitution benchmark at commit 144fe22 | AUROC (ProteinGym clinical substitutions, zero-shot, Average_AUC over proteins), unitless | 0.877 | 0.886 | PROVEAN |
What disagrees
- Other studies
- rank MutationAssessor above PROVEAN in 9 of 9 comparisons
- This study
- ranks PROVEAN above MutationAssessor in 6 of 6 comparisons
- Compared
- MutationAssessor, PROVEAN
- Study that disagrees
- An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers, OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)
- Other studies
- Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods, Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML), Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)
- Rule
- Ordering reversal; unknown
- Model identity
- Matched across studies partly through links not yet reviewed
The compared numbers
Each value links to its result record and source. Compare values within one protocol; the rule compares rankings, not raw values across protocols.
Follow-up
Current state: Not yet reviewed.
No one has reviewed this finding yet.
How to help resolve this
If you know why these studies disagree, for example a different population, metric or preprocessing step, or you have a corrected value, tell us through the contribution form. A reviewer checks every submission against its source before anything changes, and the step is added to the follow-up above.
Finding discrepancy-adecfed30105a5a9 · All contested results · How findings are made and followed up